The company is also awaiting a decision from the U.S. Food and Drug Administration (FDA) regarding the pending approval of aducanumab, its investigational human monoclonal antibody treatment for Alzheimer's disease.Biogen submitted its Biologics License Application for aducanumab to the FDA earlier this month, but previous attempts at approval have been fraught with peril.